MCA
SLS icon

Martin Capital Advisors’s SELLAS Life Sciences SLS Stock Holding History

Martin Capital Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341K Buy
+23,082
New +$159K 0.18% 69

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Martin Capital Advisors's SLS Position: Q2 2026 in Review

Martin Capital Advisors opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 23,082 shares worth $341K. The stake represents 0.18% of the portfolio and ranks #69 among its holdings.

193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Martin Capital Advisors held 23,082 shares of SELLAS Life Sciences worth $341K as of Q2 2026.
  • SELLAS Life Sciences was a new Martin Capital Advisors position in Q2 2026.
  • SELLAS Life Sciences made up 0.18% of Martin Capital Advisors's portfolio in Q2 2026, its #69 holding.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Martin Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.